Qure.ai to Debut Multimodality AI Platform for Lung Cancer Imaging at ASCO 2024
In addition to detecting missed lung nodules on X-rays, the AI-powered Qure.ai lung cancer continuum platform reportedly automates lung nodule measurement on CT scans and facilitates multimodality reporting.
Offering multimodality potential in detecting, monitoring, and reporting of lung cancer, Qure.ai will introduce an artificial intelligence (AI)-enabled lung cancer continuum platform at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Key attributes of the lung cancer continuum platform include AI-enabled lung nodule measurement and tracking of volumetric growth of disease, according to Qure.ai, the developer of the platform. The company said the lung cancer continuum platform enables monitoring of drug efficacy, provides triage prioritization, and facilitates multimodality reporting.
Key attributes of the Qure. ai lung cancer continuum platform, slated to debut at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, include AI-enabled lung nodule detection, measurement and tracking of volumetric growth of lung disease, according to Qure.ai, the developer of the platform. (Image courtesy of Qure.ai.)
Qure.ai also emphasized the capability of the lung cancer continuum platform to improve early detection of lung cancer through detection of lung nodules missed on X-rays.
“Artificial intelligence for lung cancer powers early detection, not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general health-care imaging procedures,” noted Prashant Warier, the CEO and co-founder of Qure.ai. “This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates.”
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
